Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $60.1052W HIGH $156.00
Volume
733.74 K
Value Traded
117.83 M
Short % Float
23.93%
-6.17%Week
-5.24%1 Month
+2.81%3 Month
-31.31%6 Month
+182.4%5 Year
+240.42%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.69 B
EPS (TTM)
4.37
P/E Ratio
17.80
Ent. Value
2.24 B
Total Shares
34.55 M
Float Shares
33.34 M
Insiders
3.86%
Institutions
101.96%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TMDX Catalyst Timeline
Dated clinical, regulatory and corporate events for TransMedics Group, Inc.
Past FDA Catalysts and PDUFA Decisions
How TMDX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
TransMedics Group, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every TMDX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| OCS Heart System | heart transplantation | 2021-11-04 | OCS DCD arm survival: 95%; DBD Control arm survival: 89%; adjusted OCS survival: 94%; adjusted Control survival: 90%; utilization rate: 89%Read More | TransMedics Announces Positive Top Line Results From the U.S. Randomized OCS DCD Heart Trial TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Weill DavidDirector | Buy | 1,336 16,392 held | $81.63 | 09/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TMDX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PROSIGHT MANAGEMENT, LP | 0.1 % | 497.00 K | 5.00 K |
TMDX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-06 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TMDX ranks across every disease it competes in
Competitive Position is a premium feature
See how TMDX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTMDX News
TMDXTransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
TransMedics Group, Inc. has appointed Fernando Araujo as Chief Financial Officer, effective September 21, 2026. Araujo, who has over 20 years of experience in public-company finance, will support the company's growth strategy. TransMedics also reiterated its revenue guidance for 2026, projecting $737 million to $757 million, reflecting significant year-over-year growth.
Read more →TMDXTransMedics to Present at Upcoming September Investor Conferences
TransMedics Group, Inc. will participate in two investor conferences in September 2026. The management team is scheduled for a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference and the Baird 2026 Global Healthcare Conference. These events highlight the company's commitment to advancing organ transplant therapy.
Read more →TMDX▼ -5.3%on this news
TransMedics Reports Second Quarter 2026 Financial Results
TransMedics Group, Inc. reported a 21% increase in total revenue for Q2 2026, reaching $189.9 million. The company also raised its full-year revenue guidance to between $737 million and $757 million, excluding revenue from its recent investment in PAD Aviation. However, net income fell to $14.7 million, reflecting challenges with operating expenses and margins.
Read more →TMDXTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Group, Inc. announced the granting of stock options and restricted stock units to nine employees as an inducement for their employment. This action, approved by the Compensation Committee, complies with Nasdaq Listing Rule 5635(c)(4). The stock options have a ten-year term and a vesting schedule tied to continued employment.
Read more →TMDXTransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
TransMedics Group, Inc. will present at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026. The presentation will be led by the management team and will be available via a live and archived webcast. TransMedics specializes in portable organ perfusion technologies aimed at improving organ transplant outcomes.
Read more →TMDXTransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
TransMedics Group, Inc. will announce its financial results for the second quarter of 2026 on August 4, 2026. The company is known for its innovative organ transplant technologies aimed at improving the viability and quality of donor organs. A conference call will follow the release, allowing investors to engage with management.
Read more →TMDXTransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
TransMedics Group has completed a strategic investment in PAD Aviation, a German private aviation operator, to establish a dedicated organ transplantation logistics network across Europe. This partnership aims to enhance the utilization of donor organs and replicate the successful OCS NOP model from the U.S. in the European market. The investment is seen as a significant step towards improving transplant activities within the EU.
Read more →TMDXTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. (Nasdaq: TMDX) announced the granting of non-qualified stock options and restricted stock units as inducements for new employees. On May 19, 2026, a total of 37,367 stock options and 24,848 restricted stock units were awarded to 14 employees, including Senior Vice President Matthew S. Forsyth. These grants, approved by the Compensation Committee, are in line with Nasdaq Listing Rule 5635(c)(4) and are designed to enhance employee retention through a vesting schedule. TransMedics focuses on transforming organ transplant therapy using innovative technologies.
Read more →TMDXTransMedics to Present at the William Blair 46th Annual Growth Stock Conference
TransMedics Group, Inc. will present at the William Blair 46th Annual Growth Stock Conference on June 2, 2026. The presentation will be led by the management team and is scheduled for 2:20 p.m. ET. A live and archived webcast will be available on their investor website, showcasing their advancements in organ transplant therapy.
Read more →TMDXTransMedics Reports First Quarter 2026 Financial Results
TransMedics Group, Inc. reported a 21% increase in total revenue for Q1 2026, reaching $173.9 million. The company achieved a net income of $7.3 million, although operating income fell by 52% compared to the previous year. TransMedics is focused on expanding its organ transplant logistics and has reiterated its revenue guidance for the year. The company also hosted a symposium to promote its new organ preservation technology.
Read more →TMDXTransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. has entered a definitive agreement to invest in PAD Aviation, a private aviation operator in Germany. This strategic investment aims to establish a dedicated organ transplantation air logistics network across Europe, replicating their successful U.S. model. TransMedics intends to enhance patient access to donor organs and improve transplant volumes within the EU. However, the transaction is contingent upon meeting specific closing and regulatory conditions, and risks associated with the integration of PAD Aviation and potential operational disruptions are acknowledged.
Read more →TMDXTransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. has announced an update on its clinical programs at the ISHLT 2026 Annual Meeting, introducing the Controlled Hypothermic Organ Preservation System (CHOPS). This new device aims to facilitate enrollment in the control arms of key clinical trials assessing heart and lung transplant methods. CHOPS is designed to provide stable cold storage for donor organs, differing from existing techniques. FDA has approved the IDE for these clinical trials, positioning TransMedics to strengthen its evidence base for organ transplant therapy.
Read more →TMDXTransMedics to Report First Quarter 2026 Financial Results on May 5, 2026 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. has announced it will report its financial results for the first quarter of 2026 on May 5, 2026, after market close. This report will be accompanied by a conference call at 4:30 p.m. ET. The company's ongoing efforts in organ transplant therapy continue to show promise, as it focuses on improving the quality and viability of donor organs. TransMedics is based in Andover, Massachusetts and is noted for its advancements in portable organ preservation technologies.
Read more →TMDX▲ +7.9%on this news
TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results
TransMedics Group, Inc. announced the release of a $103.3 million tax valuation allowance, leading to an $83.8 million net income tax benefit for Q4 2025. This decision reflects the company's confidence in utilizing deferred tax assets due to anticipated future income. The effective tax rate for 2025 was significantly impacted by this release, resulting in a notable difference from the standard rate.
Read more →TMDXTransMedics Reports Fourth Quarter and Full Year 2025 Financial Results
TransMedics Group, Inc. reported strong financial results for Q4 and full year 2025, with a 32% revenue increase in Q4 and a net income of $105.4 million. The company anticipates continued growth in 2026, projecting revenues between $727 million and $757 million. Strategic initiatives are planned to enhance organ transplant therapy adoption and expand operations in Europe.
Read more →TMDXTransMedics to Present at Upcoming March Investor Conferences TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. is set to participate in two upcoming investor conferences in March 2026. The company will engage in a fireside chat at the TD Cowen Annual Health Care Conference in Boston on March 2 and the Oppenheimer Healthcare MedTech & Services Conference on March 16. TransMedics specializes in transforming organ transplant therapy with its advanced technologies, aimed at improving organ quality and availability for transplantation.
Read more →TMDXTransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
TransMedics Group, Inc. announced it will release its financial results for Q4 and the full year 2025 on February 24, 2026. The management team will host a conference call at 4:30 p.m. ET to discuss the results. Investors can participate by dialing in or accessing a webcast on the company's website.
Read more →TMDXTransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial
TransMedics has received full FDA approval for its Investigational Device Exemption for the OCS ENHANCE Heart trial. This trial aims to support prolonged heart perfusion and demonstrate the superiority of the OCS Heart system over traditional cold storage methods. The trial is expected to include over 650 patients, making it the largest of its kind globally. The company is now focused on executing the trial and enrolling patients.
Read more →About TransMedics Group, Inc.
Headquarters200 MINUTEMAN ROAD, ANDOVER, MA, 01810
BIOPHARMAWATCH ELITE PLUS
Trade the next TMDX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime